The Impact of Metformin on Plasma Prolactin Levels in Antipsychotics-Treated Men With Hyperprolactinemia and Early-Onset Androgenic Alopecia
Abstract
OBJECTIVE: Metformin decreases elevated levels of pituitary hormones. Little is known about the association between the reproductive axis and hormonal effects of this drug. The purpose of our study was to investigate whether activity of the hypothalamic-pituitary-gonadal axis determines metformin action on prolactin levels in men with prolactin excess.
DESIGN/SUBJECTS/MEASUREMENTS: This prospective cohort study included two groups of men with drug-induced hyperprolactinemia and type 2 diabetes or prediabetes: men with normal hair growth (group A, n = 23) and men with late-onset androgenic alopecia (group B; n = 22). Both groups, matched for age, HOMA-IR, and prolactin concentration, were treated for 6 months with metformin. The outcomes of interest included glucose homeostasis markers (fasting glucose, glycated hemoglobin and HOMA-IR), plasma prolactin (both total and monomeric), other pituitary hormones (gonadotropins, TSH and ACTH), and peripheral hormones (testosterone, DHEAS and IGF-1).
RESULTS: Before metformin treatment, group B was characterized by higher values of LH, LH/FSH ratio, testosterone (total, free and bioavailable) and DHEAS compared to group A. Six-month metformin treatment reduced fasting glucose, glycated hemoglobin and HOMA-IR in both groups, though this effect was more pronounced in group A. The decrease in total and monomeric prolactin was observed only in group A. Their degree correlated inversely with total, free and bioavailable testosterone,…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 23 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.